Results from the WHO external quality assessment for the respiratory syncytial virus pilot, 2016-17.
RSV external quality assessment
polymerase chain reaction
respiratory syncytial viruses
Journal
Influenza and other respiratory viruses
ISSN: 1750-2659
Titre abrégé: Influenza Other Respir Viruses
Pays: England
ID NLM: 101304007
Informations de publication
Date de publication:
11 2020
11 2020
Historique:
received:
26
11
2019
revised:
19
05
2020
accepted:
24
05
2020
pubmed:
31
7
2020
medline:
20
7
2021
entrez:
31
7
2020
Statut:
ppublish
Résumé
External quality assessments (EQAs) for the molecular detection of respiratory syncytial virus (RSV) are necessary to ensure the provision of reliable and accurate results. One of the objectives of the pilot of the World Health Organization (WHO) Global RSV Surveillance, 2016-2017, was to evaluate and standardize RSV molecular tests used by participating countries. This paper describes the first WHO RSV EQA for the molecular detection of RSV. The WHO implemented the pilot of Global RSV Surveillance based on the WHO Global Influenza Surveillance and Response System (GISRS) from 2016 to 2018 in 14 countries. To ensure standardization of tests, 13 participating laboratories were required to complete a 12 panel RSV EQA prepared and distributed by the Centers for Disease Control and Prevention (CDC), USA. The 14th laboratory joined the pilot late and participated in a separate EQA. Laboratories evaluated a RSV rRT-PCR assay developed by CDC and compared where applicable, other Laboratory Developed Tests (LDTs) or commercial assays already in use at their laboratories. Laboratories performed well using the CDC RSV rRT-PCR in comparison with LDTs and commercial assays. Using the CDC assay, 11 of 13 laboratories reported correct results. Two laboratories each reported one false-positive finding. Of the laboratories using LDTs or commercial assays, results as assessed by Ct values were 100% correct for 1/5 (20%). With corrective actions, all laboratories achieved satisfactory outputs. These findings indicate that reliable results can be expected from this pilot. Continued participation in EQAs for the molecular detection of RSV is recommended.
Sections du résumé
BACKGROUND
External quality assessments (EQAs) for the molecular detection of respiratory syncytial virus (RSV) are necessary to ensure the provision of reliable and accurate results. One of the objectives of the pilot of the World Health Organization (WHO) Global RSV Surveillance, 2016-2017, was to evaluate and standardize RSV molecular tests used by participating countries. This paper describes the first WHO RSV EQA for the molecular detection of RSV.
METHODS
The WHO implemented the pilot of Global RSV Surveillance based on the WHO Global Influenza Surveillance and Response System (GISRS) from 2016 to 2018 in 14 countries. To ensure standardization of tests, 13 participating laboratories were required to complete a 12 panel RSV EQA prepared and distributed by the Centers for Disease Control and Prevention (CDC), USA. The 14th laboratory joined the pilot late and participated in a separate EQA. Laboratories evaluated a RSV rRT-PCR assay developed by CDC and compared where applicable, other Laboratory Developed Tests (LDTs) or commercial assays already in use at their laboratories.
RESULTS
Laboratories performed well using the CDC RSV rRT-PCR in comparison with LDTs and commercial assays. Using the CDC assay, 11 of 13 laboratories reported correct results. Two laboratories each reported one false-positive finding. Of the laboratories using LDTs or commercial assays, results as assessed by Ct values were 100% correct for 1/5 (20%). With corrective actions, all laboratories achieved satisfactory outputs.
CONCLUSIONS
These findings indicate that reliable results can be expected from this pilot. Continued participation in EQAs for the molecular detection of RSV is recommended.
Identifiants
pubmed: 32730685
doi: 10.1111/irv.12771
pmc: PMC7578327
doi:
Substances chimiques
RNA, Viral
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
671-677Subventions
Organisme : World Health Organization
ID : 001
Pays : International
Informations de copyright
© 2020 The Authors. Influenza and Other Respiratory Viruses Published by John Wiley & Sons Ltd.
Références
BMJ. 2019 Sep 10;366:l5021
pubmed: 31506273
Pathogens. 2019 May 21;8(2):
pubmed: 31117229
PLoS One. 2010 Nov 30;5(11):e15098
pubmed: 21152047
Influenza Other Respir Viruses. 2020 Nov;14(6):622-629
pubmed: 31444997
Influenza Other Respir Viruses. 2020 Nov;14(6):671-677
pubmed: 32730685
J Pediatr (Rio J). 2017 May - Jun;93(3):246-252
pubmed: 27889321
Emerg Infect Dis. 2017 Feb;23(2):264-271
pubmed: 28098528
J Clin Microbiol. 2015 Dec;53(12):3738-49
pubmed: 26354816
Influenza Other Respir Viruses. 2018 Sep;12(5):566
pubmed: 29437295
BMC Infect Dis. 2017 Dec 20;17(1):785
pubmed: 29262784
J Clin Microbiol. 2006 Jul;44(7):2382-8
pubmed: 16825353
Intervirology. 2019;62(3-4):112-115
pubmed: 31542785
J Virol. 2010 Aug;84(15):7500-12
pubmed: 20504933
Clin Infect Dis. 2017 Jun 15;64(suppl_3):S337-S346
pubmed: 28575373
Expert Rev Mol Diagn. 2018 Jul;18(7):617-629
pubmed: 29890085
Arch Virol. 2020 May;165(5):1069-1077
pubmed: 32144544
Influenza Other Respir Viruses. 2013 Nov;7(6):1008-12
pubmed: 23782406
Lancet. 2010 May 1;375(9725):1545-55
pubmed: 20399493
Lancet Glob Health. 2017 Oct;5(10):e984-e991
pubmed: 28911764
Clin Microbiol Rev. 2017 Jan;30(1):277-319
pubmed: 27903593
J Infect Dis. 2017 Jan 1;215(1):4-7
pubmed: 27694634
Clin Microbiol Infect. 2008 Dec;14(12):1173-6
pubmed: 19046164
J Virol. 2015 Apr;89(7):3444-54
pubmed: 25609811